Artivion, Inc.
corporate_fare Company Profile
Artivion, Inc. (NYSE:AORT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 12 items for AORT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-07, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for AORT spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Artivion Q2 2026: Revenue Up 11% but Net Loss of $(13.5)M on Endospan Deal Costs and Contingent Consideration Charge
- Artivion Q2 2026: Revenue Climbs 11%, but Acquisition Costs Deepen Net Loss; Guidance Holds Steady
- FDA Approves Artivion's AMDS Hybrid Prosthesis for Acute Aortic Dissections, Targeting $150M Market
- Artivion Finalizes $135M Endospan Acquisition, Securing FDA-Approved Aortic Arch System
- Artivion Reports Strong Q1 Growth, Profitability Turnaround, and Confirms Endospan Acquisition
Financial Snapshot
Short Interest & Short Volume
5.43 days to coverFINRA reported short interest of 3,284,198 shares in AORT as of the September 15, 2026 settlement, a 12.2% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On October 2, 2026, 67.6% of AORT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.